Post-earnings recap
Reported
Wed, Nov 9, 2022
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
50%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Celldex Therapeutics reported a loss of $0.57 per share, with no revenue figures disclosed. The stock fell by 5.67% following the earnings release, likely due to the lack of guidance and clarity on future performance. Investors may be concerned about the company's direction without specific targets or revenue expectations.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.57 | N/A | +0.00% |
| Revenue | N/A | N/A | N/A |
Management expressed a cautious outlook without offering specific guidance. They emphasized their commitment to ongoing clinical development.
Management did not provide specific guidance for the upcoming quarters.
The company remains focused on advancing its clinical programs.